Compare SPOK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOK | IKT |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 240.1M |
| IPO Year | 2004 | 2020 |
| Metric | SPOK | IKT |
|---|---|---|
| Price | $11.14 | $1.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $14.00 | $5.00 |
| AVG Volume (30 Days) | 158.7K | ★ 1.2M |
| Earning Date | 04-29-2026 | 03-26-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | 2.74 | ★ 57.76 |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $139,708,000.00 | N/A |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | N/A | $33.33 |
| P/E Ratio | $14.80 | ★ N/A |
| Revenue Growth | ★ 1.49 | N/A |
| 52 Week Low | $10.81 | $1.33 |
| 52 Week High | $19.31 | $2.37 |
| Indicator | SPOK | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 46.81 |
| Support Level | N/A | $1.43 |
| Resistance Level | $13.87 | $1.74 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 52.31 | 35.87 |
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.